Response to the letter regarding article “Metabolic syndrome is associated with different clinical outcome after cardiac resynchronization therapy in patients with ischemic and non-ischemic cardiomyopathy” by Szepietowska, Barbara & Zareba, Wojciech
Response to the letter regarding article  
“Metabolic syndrome is associated with  
different clinical outcome after cardiac  
resynchronization therapy in patients with  
ischemic and non-ischemic cardiomyopathy”
We would like to thank the Authors for the 
commentary to our paper [1]. The commentary 
furthermore highlighted the importance of fuel 
metabolism in failing heart and significance of 
the intervention strategies, which may directly 
or indirectly target major metabolic pathways 
balancing glucose and free fatty acids metabolism. 
It should be noted that in Multicenter Automatic 
Deffibrillator Implantation Trial with Cardiac Re-
synchronization Therapy (MADIT-CRT) popula-
tion, only 15 subjects were treated with trimetazi-
dine, not allowing further evaluation.
Our report demonstrated that patients with 
metabolic syndrome (MS) depending on etiology for 
heart failure (HF) presented with different response 
to cardiac resynchronization therapy (CRT). MS pa-
tients derive significant benefit from CRT if present 
with non-ischemic cardiomyopathy, whereas obese 
patients without MS show no significant reduction 
in events. This study suggests that the risk for HF 
and death may be modulated by presence of MS, 
a clinical surrogate for insulin resistance [1].
The current hypothesis is that CRT, among 
other effects, for example on cardiac remodeling, 
may also improve fuel metabolism of the failing 
heart. It is possible that improvement in fuel me-
tabolism may correspond to better clinical response 
to CRT and reduction in risk for HF and death. In 
animal studies, CRT treatment was attributed to 
activation of important metabolic and insulin signal 
transduction protein kinase B pathway (PKB) known 
as Akt [2]. It is generally accepted that falling heart 
switches its fuel metabolism from long chain fatty 
acids to glucose [3] but in people with MS with in-
sulin resistance as predominant pathological factor, 
glucose is less available for utilization. Therefore, 
activation of defective PKB/AKt by CRT may poten-
tially modulate glucose uptake in the failing heart.
Although it is only speculative, this study also 
suggests that intrinsic properties of myocardium 
fuel metabolism affected by MS may play a role 
in response to CRT. Future studies are needed to 
investigate mechanism of CRT in relation to myo-
cardium fuel metabolism and cellular responses 
in falling heart.
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